Latest & greatest articles for hypertension

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hypertension or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hypertension and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hypertension

1. Treatment of Masked Hypertension with a Chinese Herbal Formula: A Randomized, Placebo-Controlled Trial

.-H.Y.). PMID: 33019798 DOI: Item in Clipboard Full-text links Cite Display options Display options Format Abstract Background: Masked hypertension is associated with adverse cardiovascular outcomes. Nonetheless, no randomized controlled trials exist in the treatment of masked hypertension. The aim of this randomized, placebo-controlled trial was to investigate the efficacy and safety of blood pressure (BP)-lowering treatment with a Chinese herbal formula, gastrodia-uncaria granules, in patients (...) with masked hypertension. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: . Keywords: blood pressure monitoring, ambulatory; masked hypertension; medicine, traditional Chinese; randomized controlled trial. Similar articles Wei FF, Li Y, Zhang L, Shan XL, Cheng YB, Wang JG, Yang CH, Staessen JA. Wei FF, et al. Am J Hypertens. 2016 Mar;29(3):326-31. doi: 10.1093/ajh/hpv106. Epub 2015 Jul 6. Am J Hypertens. 2016. PMID: 26150543 Clinical Trial. Shimada K, Ogihara T, Saruta T, Kuramoto K

2020 EvidenceUpdates

2. Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis Full Text available with Trip Pro

Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving (...) and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis , , , , , , , Affiliations Expand Affiliations 1 Departamento de Medicina Preventiva, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Botucatu, n° 740, Vila Clementino, São Paulo, SP CEP 04023-062 Brazil. 2 Sociedade Brasileira de Diabetes-SBD, Rua Afonso Braz, 579, Salas 72/74, Vila Nova Conceição, São Paulo, SP CEP 04511-011 Brazil. 3 Programa de Pós-Graduação Em Endocrinologia

2020 EvidenceUpdates

3. Niraparib (Zejula): reports of severe hypertension and posterior reversible encephalopathy syndrome (PRES), particularly in early treatment

in blood pressure during treatment, manage hypertension with antihypertensives and if necessary, consider treatment interruption and subsequent adjustment of the niraparib dose as advised in discontinue niraparib in case of hypertensive crisis or if medically significant hypertension cannot be adequately controlled with antihypertensive therapy in cases of PRES, discontinue niraparib and treat specific symptoms including hypertension report any suspected adverse drug reactions associated with niraparib (...) cookies. You can at any time. Hide Show or hide search Search on GOV.UK Search National restrictions in England from 5 November Take action now for new rules in 2021 Niraparib (Zejula▼): reports of severe hypertension and posterior reversible encephalopathy syndrome (PRES), particularly in early treatment Increase the frequency of blood pressure monitoring to at least weekly for the first 2 months, and then monitor monthly for the first year and periodically thereafter during treatment, following

2020 MHRA Drug Safety Update

4. High Blood Pressure in Children and Adolescents: Screening

pressure; however, many children identified as having elevated blood pressure will not have hypertension. One study was done in a hypertension clinic in Greece, possibly limiting generalizability to a primary care population in the United States. The other study took place in a high school clinic . Association With Adult Hypertension and Cardiovascular Disease Ten longitudinal studies provided evidence on the association between elevated blood pressure in childhood and adulthood (7 studies), carotid (...) and that the balance of benefits and harms cannot be determined. How Does Evidence Fit With Biological Understanding? The proportion of children with primary hypertension who revert to normal blood pressure over time, without any intervention, and those who will continue to have hypertension in adulthood is unknown. Persistent elevation of blood pressure in adults is an established risk factor for cardiovascular and cerebrovascular disorders and renal impairment. However, these conditions are often distant future

2020 U.S. Preventive Services Task Force

5. Diagnosis of hypertension using ambulatory blood pressure monitoring in patients with clinic blood pressure ? 140/90mmHg and ? 180/110mmHg

Diagnosis of hypertension using ambulatory blood pressure monitoring in patients with clinic blood pressure ? 140/90mmHg and ? 180/110mmHg 1 Public Summary Document Application No. 1572 – Diagnosis of hypertension using ambulatory blood pressure monitoring in patients with clinic blood pressure = 140/90mmHg and = 180/110mmHg Applicant: High Blood Pressure Research Council of Australia Inc. Date of MSAC consideration: MSAC 78 th Meeting, 3 April 2020 Context for decision: MSAC makes its advice (...) to comparative safety, clinical effectiveness and cost-effectiveness, MSAC supported MBS funding of diagnosis of hypertension using ambulatory blood pressure monitoring (ABPM) in patients with clinic blood pressure =140/90 mmHg and =180/110 mmHg on the basis that ABPM is the accepted gold standard for the diagnosis of high blood pressure in primary care. MSAC accepted that ABPM was cost-effective, but advised that the proposed fee should not include the cost of the consumables. MSAC was concerned

2020 Medical Services Advisory Committee

6. SMFM Special Statement: Checklist for postpartum discharge of women with hypertensive disorders

SMFM Special Statement: Checklist for postpartum discharge of women with hypertensive disorders Publications & Guidelines | SMFM.org - The Society for Maternal-Fetal Medicine Navigate | Search Search » » SMFM Special Statement: Checklist for postpartum discharge of women with hype... SMFM Special Statement: Checklist for postpartum discharge of women with hypertensive disorders The Society for Maternal-Fetal Medicine presents a checklist for the postpartum discharge of women with hypertensive (...) disorders and suggests implementation strategies and quality indicators. Tags: , , Categories: © 2000-2020, Society for Maternal-Fetal Medicine. All rights reserved The Pregnancy Meeting is a Trademark of the Society for Maternal-Fetal Medicine. Use of this Web site constitutes acceptance of Stay Connected

2020 Society for Maternal-Fetal Medicine

7. Radiologic Management of Portal Hypertension

biopsy remains the reference standard for the assessment and diagnosis of cirrhosis, hepatic vein catheterization with measurement of the hepatic venous pressure gradient (HVPG) is currently the benchmark technique for determining portal pressure. The HVPG quantifies the degree of portal hypertension due to sinusoidal resistance to blood flow. The HVPG is calculated as the difference between the wedged hepatic venous pressure and the free hepatic venous pressure. A normal HVPG is between 1 and 5 mmHg (...) ; Bill S. Majdalany, MD c ; Charles Y. Kim, MD d ; Osmanuddin Ahmed, MD e ; Sumeet K. Asrani, MD, MSc f ; Brooks D. Cash, MD g ; Jens Eldrup-Jorgensen, MD h ; A. Tuba Kendi, MD i ; Matthew J. Scheidt, MD j ; David M. Sella, MD k ; Karin E. Dill, MD l ; Eric J. Hohenwalter, MD. m Summary of Literature Review Introduction/Background Portal hypertension is a common clinical syndrome, hemodynamically defined by a pathological increase of the portal pressure and by the formation of portal-systemic

2020 American College of Radiology

8. Alcohol intake reduction for controlling hypertension. (Abstract)

Alcohol intake reduction for controlling hypertension. High blood pressure constitutes one of the leading causes of mortality and morbidity all over the world. At the same time, heavy drinking increases the risk for developing cardiovascular diseases, including cardiomyopathy, hypertension, atrial arrhythmias, or stroke. Several studies have already assessed specifically the relationship between alcohol intake and hypertension. However, the potential effect on blood pressure of alcohol intake (...) reduction interventions is largely unknown.To assess the effect of any intervention to reduce alcohol intake in terms of blood pressure decrease in hypertensive people with alcohol consumption compared to a control intervention or no intervention at all. To determine additional effects related to mortality, major cardiovascular events, serious adverse events, or quality of life.The Cochrane Hypertension Information Specialist searched the following databases for randomised controlled trials up to June

2020 Cochrane

9. 5 classes of antihypertensive drugs were not linked to positive COVID-19 test results or severe COVID-19. (Abstract)

5 classes of antihypertensive drugs were not linked to positive COVID-19 test results or severe COVID-19. Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020;382:2441-8. 32356628.

2020 Annals of Internal Medicine

10. Trends in Blood Pressure Control Among US Adults With Hypertension, 1999-2000 to 2017-2018. (Abstract)

Trends in Blood Pressure Control Among US Adults With Hypertension, 1999-2000 to 2017-2018. Controlling blood pressure (BP) reduces the risk for cardiovascular disease.To determine whether BP control among US adults with hypertension changed from 1999-2000 through 2017-2018.Serial cross-sectional analysis of National Health and Nutrition Examination Survey data, weighted to be representative of US adults, between 1999-2000 and 2017-2018 (10 cycles), including 18 262 US adults aged 18 years (...) or older with hypertension defined as systolic BP level of 140 mm Hg or higher, diastolic BP level of 90 mm Hg or higher, or use of antihypertensive medication. The date of final data collection was 2018.Calendar year.Mean BP was computed using 3 measurements. The primary outcome of BP control was defined as systolic BP level lower than 140 mm Hg and diastolic BP level lower than 90 mm Hg.Among the 51 761 participants included in this analysis, the mean (SD) age was 48 (19) years and 25 939 (50.1

2020 JAMA

11. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. (Abstract)

Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. This is the second update of the review first published in 2017. Hypertension is a prominent preventable cause of premature morbidity and mortality. People with hypertension and established cardiovascular disease are at particularly high risk, so reducing blood pressure to below standard targets may be beneficial. This strategy could reduce cardiovascular mortality and morbidity but could also (...) 9484 participants. Mean follow-up was 3.7 years (range 1.0 to 4.7 years). All RCTs provided individual participant data. None of the included studies was blinded to participants or clinicians because of the need to titrate antihypertensives to reach a specific blood pressure goal. However, an independent committee blinded to group allocation assessed clinical events in all trials. Hence, we assessed all trials at high risk of performance bias and low risk of detection bias. Other issues

2020 Cochrane

12. Pharmacotherapy for hyperuricaemia in hypertensive patients. (Abstract)

Pharmacotherapy for hyperuricaemia in hypertensive patients. This is the second update of this systematic review. High blood pressure represents a major public health problem. Worldwide, approximately one-fourth of the adult population has hypertension. Epidemiological and experimental studies suggest a link between hyperuricaemia and hypertension. Hyperuricaemia affects 25% to 40% of those with untreated hypertension; a much lower prevalence has been reported in those with normotension (...) or in the general population. However, whether lowering serum uric acid (UA) might lower blood pressure (BP), is an unanswered question.To determine whether UA-lowering agents reduce BP in people with primary hypertension or prehypertension, compared with placebo.The Cochrane Hypertension Information Specialist searched the following databases for randomised controlled trials up to May 2020: the Cochrane Hypertension Specialised Register, CENTRAL 2018, Issue 12, MEDLINE (from 1946), Embase (from 1974

2020 Cochrane

13. Pulmonary Artery Denervation for Patients With Residual Pulmonary Hypertension After Pulmonary Endarterectomy

pulmonary hypertension (CTEPH) after pulmonary endarterectomy (PEA). Objectives: This study sought to assess the safety and efficacy of PADN using remote magnetic navigation in patients with residual CTEPH after PEA. Methods: Fifty patients with residual CTEPH despite medical therapy at least 6 months after PEA, who had mean pulmonary artery pressure ≥25 mm Hg or pulmonary vascular resistance (PVR) > 400 dyn‧s‧cm -5 based on right heart catheterization were randomized to treatment with PADN (PADN group (...) Pulmonary Artery Denervation for Patients With Residual Pulmonary Hypertension After Pulmonary Endarterectomy Pulmonary Artery Denervation for Patients With Residual Pulmonary Hypertension After Pulmonary Endarterectomy - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get

2020 EvidenceUpdates

14. Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: A systematic review and meta-analysis Full Text available with Trip Pro

and objective: Controversy has arisen in the scientific community on whether the use of renin-angiotensin system (RAS) inhibitors in the context of COVID-19 would be beneficial or harmful. A meta-analysis of eligible studies comparing the occurrence of severe and fatal COVID-19 in infected hypertensive patients who were under treatment with angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) vs no treatment or other antihypertensives was conducted. Methods: PubMed, Google (...) Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: A systematic review and meta-analysis Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: A systematic review and meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19

2020 EvidenceUpdates

15. Synopsis of the 2020 U.S. Department of Veterans Affairs/U.S. Department of Defense Clinical Practice Guideline: The Diagnosis and Management of Hypertension in the Primary Care Setting. (Abstract)

) system.This synopsis summarizes key features of the guideline in several key areas: the measurement of blood pressure, the definition of hypertension, target treatment goals, and nonpharmacologic and pharmacologic treatment of essential and resistant hypertension. (...) Synopsis of the 2020 U.S. Department of Veterans Affairs/U.S. Department of Defense Clinical Practice Guideline: The Diagnosis and Management of Hypertension in the Primary Care Setting. In January 2020, the U.S. Department of Veterans Affairs (VA) and the U.S. Department of Defense (DoD) approved a joint clinical practice guideline for the diagnosis and management of hypertension in the primary care setting.The VA/DoD Evidence-Based Practice Work Group convened a joint VA/DoD guideline

2020 Annals of Internal Medicine

16. Hypertension - Diagnosis and Management

hypertension refers to the untreated condition in which BP is elevated in the office but is normal when measured by ambulatory blood pressure monitoring (ABPM), home blood pressure measurement (HBPM), or both. Masked hypertension refers to untreated patients in whom the BP is normal in the office but is elevated when measured by HBPM or ABPM. Classification Based on the average BP recorded, hypertension is classified as High-Normal, Stage 1, Stage 2, or Stage 3 (Note: Figure 1 lists MOBP values only (...) device is recommended in patients with regular heart rate. [ Strong Recommendation, Strong Evidence ] Hypertension is diagnosed in adults when automated office blood pressure reading is ≥ 135/85 in the higher BP arm. [ Strong Recommendation, Strong Evidence ] When a manual office blood pressure device (MOBP) is used hypertension is diagnosed at ≥ 140/90. [ Strong Recommendation, Strong Evidence ] Consider 24-hour ambulatory blood pressure monitoring, or standardized home blood pressure monitoring

2020 Clinical Practice Guidelines and Protocols in British Columbia

17. Three-Year Outcomes of Bariatric Surgery in Patients With Obesity and Hypertension : A Randomized Clinical Trial. (Abstract)

Three-Year Outcomes of Bariatric Surgery in Patients With Obesity and Hypertension : A Randomized Clinical Trial. Midterm effects of bariatric surgery on patients with obesity and hypertension remain uncertain.To determine the 3-year effects of Roux-en-Y gastric bypass (RYGB) on blood pressure (BP) compared with medical therapy (MT) alone.Randomized clinical trial. (ClinicalTrials.gov: NCT01784848).Investigator-initiated study at Heart Hospital (HCor), São Paulo, Brazil.Patients (...) with hypertension receiving at least 2 medications at maximum doses or more than 2 medications at moderate doses and with a body mass index (BMI) between 30.0 and 39.9 kg/m2 were randomly assigned (1:1 ratio).RYGB plus MT or MT alone.The primary outcome was at least a 30% reduction in total number of antihypertensive medications while maintaining BP less than 140/90 mm Hg. Key secondary outcomes were number of antihypertensive medications, hypertension remission, and BP control according to current guidelines

2020 Annals of Internal Medicine

18. CCS/CTS Position Statement on Pulmonary Hypertension Full Text available with Trip Pro

Thoracic Society clinical practice guideline update. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. 2019; 3 : 177-198 Figure 1 An algorithm for the work-up of pulmonary hypertension (PH). ABG, arterial blood gas; CHD, congenital heart disease; CT, computed tomography; CTD, connective tissue disease; CTEPH, chronic thromboembolic pulmonary hypertension; DLCO, diffusion capacity of the lung for carbon monoxide; ECG, electrocardiogram; HR-CT, high-resolution computed tomography; mPAP (...) these modalities, particularly at high pulmonary artery pressure (PAP), and estimation of RA pressure according to inferior vena cava size and collapsibility is sometimes inaccurate. Fisher M.R. Forfia P.R. Chamera E. et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009; 179 : 615-621 , Rich J.D. Shah S.J. Swamy R.S. Kamp A. Rich S. Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients

2020 Canadian Cardiovascular Society

19. Pulmonary arterial hypertension: sometimes drug-induced

of fenfluramine and dexfenfluramine, and implicated many other amphetamines. In 2016, 1,273 observations of pulmonary arterial hypertension attributed to benfluorex were reported to the French Health Products Agency. The number of drugs known to provoke pulmonary arterial hypertension has increased over the years. These include anti-tumour treatments such as dasatinib or related drugs, immunosuppressants such as leflunomide or omalizumab and various other drugs such as interferons or sofosbuvir. The disorders (...) sometimes improve with withdrawal from the drug responsible. When pulmonary arterial hypertension is suspected to be the cause of respiratory disorders, it can be of great help to patients to consider the possibility that it was induced by a drug. ©Prescrire 1 July 2020 Source: "Drug-induced pulmonary arterial hypertension" Prescrire International 2020; 29 (217): 180-183. Subscribers only. Enjoy full access to Prescrire International, and support independent information Share See also: "Methylphenidate

2020 Prescrire

20. Withdrawal of antihypertensive drugs in older people. Full Text available with Trip Pro

of the antihypertensive medicine.We compared the intervention of discontinuing or reducing antihypertensive medication to usual treatment using mean differences (MD) and 95% confidence intervals (95% CIs) for continuous variables and we used Peto odds ratios (ORs) and 95% CI for binary variables. Our primary outcomes included: mortality, myocardial infarction, development of adverse drug reactions or adverse drug withdrawal reactions. Secondary outcomes included: blood pressure, hospitalisation, stroke, success (...) certainty of evidence), for myocardial infarction 1.86 (95% CI 0.19 to 17.98; very low certainty of evidence) and for stroke 1.44 (95% CI 0.25 to 8.35; low certainty of evidence). Blood pressure was higher in the discontinuation group than the continuation group (systolic blood pressure: MD = 9.75 mmHg, 95% CI 7.33 to 12.18; and diastolic blood pressure: MD = 3.5 mmHg, 95% CI 1.82 to 5.18; low certainty of evidence). For the development of adverse events, meta-analysis was not possible; antihypertensive

2020 Cochrane